🩸 IMPEDE VTE Score (Myeloma)
UseWhen to use: MM at chemotherapy/IMiD start when choosing thromboprophylaxis intensity.
Strata≤3 lower; 4–7 intermediate; ≥8 higher 6-month VTE band — escalate prophylaxis per pathway.
LimitsWhen not to use: non-myeloma cancer VTE (use Khorana etc.). · Pitfall: omitting negative ppx/ethnicity points. · Weigh bleed risk before anticoagulants.
SourceSanfilippo EM et al. IMPEDE VTE
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Myeloma-specific.
When to use
When to use: MM at chemotherapy/IMiD start when choosing thromboprophylaxis intensity.
How it works
IMiD +4, BMI≥25 +1, pelvic/hip/femur fx +4, ESA +1, doxorubicin +3, dex LD +2/HD +4, Asian −3, prior VTE +5, CVC +2, ppx LMWH/ASA −3 or therapeutic −4.
Key points
- Myeloma-specific.
- ≥8 high cue.
- Next: NCCN-style prophylaxis + bleed review.
References
- Sanfilippo EM et al. IMPEDE VTE
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Immunomodulatory drug (IMiD) | No (0) |
|---|---|
| BMI ≥25 kg/m² | No (0) |
| Pelvic, hip, or femur fracture | No (0) |
| Erythropoiesis-stimulating agent | No (0) |
| Doxorubicin | No (0) |
| Dexamethasone | Low-dose ≤160 mg/month (+2) |
| Asian / Pacific Islander ethnicity | No (0) |
| History of VTE before myeloma | No (0) |
| Tunneled line / central venous catheter | No (0) |
| Existing thromboprophylaxis | Prophylactic LMWH or aspirin (−3) |
→IMPEDE VTE-1pts
- Band：≤3 low — aspirin often considered per NCCN-style pathways
| Immunomodulatory drug (IMiD) | No (0) |
|---|---|
| BMI ≥25 kg/m² | No (0) |
| Pelvic, hip, or femur fracture | No (0) |
| Erythropoiesis-stimulating agent | No (0) |
| Doxorubicin | No (0) |
| Dexamethasone | None (0) |
| Asian / Pacific Islander ethnicity | No (0) |
| History of VTE before myeloma | No (0) |
| Tunneled line / central venous catheter | No (0) |
| Existing thromboprophylaxis | None (0) |
→IMPEDE VTE0pts
- Band：≤3 low — aspirin often considered per NCCN-style pathways
Verification & sources · governance
FAQ
Frequently asked questions
- Does IMPEDE VTE Score (Myeloma) upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is IMPEDE VTE Score (Myeloma) calculated in practice? Can you show a worked example?
- Inputs: Immunomodulatory drug (IMiD) No (0), BMI ≥25 kg/m² No (0), Pelvic, hip, or femur fracture No (0), Erythropoiesis-stimulating agent No (0), Doxorubicin No (0), Dexamethasone Low-dose ≤160 mg/month (+2), Asian / Pacific Islander ethnicity No (0), History of VTE before myeloma No (0)… → Result: IMPEDE VTE -1 pts（Band: ≤3 low — aspirin often considered per NCCN-style pathways） Inputs: Immunomodulatory drug (IMiD) No (0), BMI ≥25 kg/m² No (0), Pelvic, hip, or femur fracture No (0), Erythropoiesis-stimulating agent No (0), Doxorubicin No (0), Dexamethasone None (0), Asian / Pacific Islander ethnicity No (0), History of VTE before myeloma No (0)… → Result: IMPEDE VTE 0 pts（Band: ≤3 low — aspirin often considered per NCCN-style pathways）